Zanubrutinib inotenderwa neUSFDA yekudzokorora kana refractory follicular lymphoma

Kurume 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) pamwe chete neobinutuzumab yakapihwa mvumo yekukurumidzira neFood and Drug Administration yekurapa kudzokazve kana refractory follicular lymphoma (FL).

Basa reImmunotherapy Mukurapa Lymphoma

Kana iwe uri kuverenga izvi, iwe kana pamwe mumwe wevadiwa vako ari parwendo rwusina anomboronga kutora-nzira yekutarisana negomarara. Isu tinonzwisisa kuti mugwagwa uyu uzere nekusagadzikana, kutya, uye nguva dzaunonzwa ..

MOTO - T Cell kurapwa, CAR T Therapy, MOTO T-Cell, chimeric agent

Dive Yakadzika muCAR T Cell Therapy: Inoshanda Sei?

Ziva sainzi kuseri kweCAR T Cell kurapwa muIndia! Ongorora kuti iyi shanduko yekurapa inoshandura sei maseru edziviriro yako kuita cancer fighters. Verenga blog yedu izvozvi kuti udzidze zvakawanda nezve ichi chishamiso kurapa uye sei ..

MOTO T-Cell, CAR kurapwa, immunotherapy, T cell kurapa

Ko CAR T-Cell Therapy Inowanikwa muIndia?

Wakambozvibvunza here kana paine nzira ine simba yekurwisa cancer? Zvino chimbofungidzira kana rimwe zuva ukawana rayi retariro mukurwira kwako gomarara, kurapwa kunoshandisa simba remuviri wako wega immune system kunanga ..

B-cell lymphoma, DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin

Polatuzumab vedotin-piiq inotenderwa neUSFDA kune yaimbove isina kurapwa yakapararira yakakura B-cell lymphoma, isina kutsanangurwa neimwe nzira, uye yepamusoro-giredhi B-cell lymphoma.

Chivabvu 2023: Kune varwere vakura vane giredhi repamusoro B-cell lymphoma (HGBL), isina kutsanangurwa neimwe nzira (NOS), kana kuparadzira hombe B-cell lymphoma (DLBCL) vasina kumbowana kurapwa uye vane International Prognostic Inde.

Carteyva, JW Therapeutics, lymphoma, inoratidzira follicular lymphoma, RELIANCE kudzidza, relmacabtagene autoleucel

JW Therapeutics Inozivisa NMPA Mvumo yeRelmacabtagene Autoleucel Jekiseni muVarwere vane Relapsed kana Refractory Follicular Lymphoma.

SHANGHAI, CHINA, Gumiguru 10, 2022 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisana nekugadzira, kugadzira, uye kutengesa zvigadzirwa zvema cell immunotherapy, yakazivisa kuti Na.

ASTCT, CIBMTR, Yakakura B-cell lymphoma, Matthew Frank, Miltenyi Biotec, Stanford University

Novel kurapwa chinangwa chevarwere ve lymphoma vanodzokera shure mushure meCAR-T kurapwa

Kukadzi 2023: Mhedzisiro yemuyedzo yakaratidza kuti novel chimeric antigen receptor T-cell therapy yakapa mhinduro kune vanhu vakuru vane yakakura B-cell lymphoma vaive vadzokera shure vachitevera yapfuura CAR-T. Maererano ne stati..

Eli Lilly uye Kambani, FDA, Zvokudya uye Drug Administration, Jaypirca, Mantle cell lymphoma, MCLs, pirtobrutinib

Mvumo yekukurumidza inopihwa neFDA kune pirtobrutinib yekudzoreredza kana refractory mantle cell lymphoma.

Kukadzi 2023: Mvumo yekukurumidza inopihwa neFDA kune pirtobrutinib (Jaypirca, Eli Lilly uye Kambani) yekudzokazve kana refractory mantle cell lymphoma. MuBRUIN (NCT03740529), yakavhurika-label, multicenter, imwe-ruoko muyedzo wepirtobr..

BeiGene USA, BRUKINSA, chisingaperi lymphocytic leukemia, SEQUOIA, diki lymphocytic lymphoma

Zanubrutinib inotenderwa neFDA kune chronic lymphocytic leukemia kana diki lymphocytic lymphoma

Kukadzi 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) inotenderwa neFDA kune chronic lymphocytic leukemia (CLL) kana diki lymphocytic lymphoma (SLL). SEQUOIA yakashandiswa kuongorora kushanda muvarwere veCLL/SLL vakanga vasina kuwana ..

Adcetris, brentuximab vedotin, Hodgkin lymphoma yekare, Iyo kambani Seagen Inc

Brentuximab vedotin inotenderwa neFDA pamwe chete nechemotherapy yevana varwere vane classical Hodgkin lymphoma.

Mbudzi 2022: Iko kusanganiswa kwe doxorubicin, vincristine, etoposide, prednisone, uye cyclophosphamide ine brentuximab vedotin (Adcetris, Seagen, Inc.) yakabvumidzwa neFood and Drug Administration kuti ishandiswe muvana.